Group 1: Company Announcements - 合富中国's stock price increased by 256.29% over 14 trading days, significantly outperforming the industry and Shanghai Composite Index, leading to a suspension for verification starting November 17 [1] - 工业富联's GB300 achieved mass production in Q3, with improved yield and testing efficiency, positively impacting Q4 gross margin [2] - 天孚通信's controlling shareholder plans to transfer 8.5 million shares, representing 1.09% of total equity, due to personal funding needs [4] - 璞泰来 plans to invest 7.6 billion yuan in a new integrated film coating project, aiming to meet growing demand in the battery and energy storage sectors [5] - 电投能源 intends to acquire 100% of Baiyin Hua Coal Power for 11.149 billion yuan, financing through share issuance and cash [6] - 中微公司 reported that a shareholder completed a reduction of 12.52 million shares, totaling 3.351 billion yuan [7] - 瑞德智能 plans to invest 10 million yuan in a leading company in the power plant robotics sector [8] - 盘古智能 aims to acquire control of a petrochemical company by purchasing 11.97% of its shares for 24.64 million yuan [9] - 泰达股份 signed a memorandum for a waste-to-energy project in Egypt [10] - 杭氧股份 is set to establish a venture capital fund focusing on low-temperature technology and nuclear fusion [11] Group 2: Financial Performance and Regulatory Approvals - 复星医药's subsidiary received FDA approval for a biosimilar drug, with applications pending in China and Europe [21] - 长春高新 received approval for a clinical trial of a new growth hormone drug, with no similar products currently available in China [20] - 海辰药业 obtained a drug registration certificate for a new injection product [22] - 上海机场 reported a 12.46% year-on-year increase in passenger throughput for October [23] Group 3: Shareholder Actions - 深桑达 A plans to publicly transfer 80% of a subsidiary's shares with a minimum price of 1.857 billion yuan [12] - 中电港's major shareholder reduced its stake by 1% between October 31 and November 13 [15] - 康龙化成's major shareholders plan to collectively reduce their holdings by up to 1.5% [16] - 科兴制药's controlling shareholder intends to transfer 5% of its shares [17]

Core Viewpoint - The company 康龙化成 (300759.SZ) has announced that its major shareholders, 深圳市信中康成投资合伙企业 and 深圳市信中龙成投资合伙企业, plan to reduce their holdings in the company through legal means recognized by the Shenzhen Stock Exchange [1] Shareholder Reduction Plans - 深圳市信中康成 plans to reduce its holdings by up to 8.891 million shares, which represents 0.50% of the company's total share capital, within three months starting from December 8, 2025 [1] - 深圳市信中龙成 plans to reduce its holdings by up to 17.782 million shares, which represents 1% of the company's total share capital, within the same three-month period starting from December 8, 2025 [1]

Core Viewpoint - Kanglong Chemical (300759.SZ) announced that major shareholders plan to reduce their holdings in the company through legal means recognized by the Shenzhen Stock Exchange [1] Shareholder Reduction Plans - Shenzhen Xinchongkangcheng Investment Partnership (Limited Partnership) plans to reduce its holdings by up to 8.891 million shares, representing 0.50% of the company's total share capital, within three months starting from December 8, 2025 [1] - Shenzhen Xinchonglongcheng Investment Partnership (Limited Partnership) intends to reduce its holdings by up to 17.782 million shares, accounting for 1% of the company's total share capital, within the same three-month period starting from December 8, 2025 [1]

Core Viewpoint - Kanglong Chemical (SZ 300759) announced a share reduction plan from major shareholders, which may impact the stock's performance and investor sentiment [1] Shareholder Reduction Plan - Shenzhen Xinchongkang Investment Partnership plans to reduce its holdings by up to approximately 8.89 million shares, accounting for 0.5% of the total share capital, within three months starting from December 8, 2025 [1] - Shenzhen Xinchonglong Investment Partnership plans to reduce its holdings by up to approximately 17.78 million shares, accounting for 1% of the total share capital, within the same timeframe [1] Financial Performance - For the year 2024, Kanglong Chemical's revenue composition is as follows: 99.95% from scientific research and technical services, and 0.05% from other businesses [1] - As of the report date, Kanglong Chemical's market capitalization stands at 56 billion yuan [1]

Core Viewpoint - The company announced that major shareholders plan to reduce their holdings in the company through legal means recognized by the Shenzhen Stock Exchange [1] Shareholder Reduction Plans - Shenzhen Xinchongkangcheng Investment Partnership (Limited Partnership) holds 223,488,310 shares, approximately 12.57% of the total share capital, and plans to reduce up to 8,890,977 shares, which is 0.50% of the total share capital, within three months starting from December 8, 2025 [1] - Shenzhen Xindlongcheng Investment Partnership (Limited Partnership) holds 28,498,500 shares, approximately 1.60% of the total share capital, and plans to reduce up to 17,781,955 shares, which is 1% of the total share capital, within the same three-month period starting from December 8, 2025 [1]

Core Viewpoint - 康龙化成 announced a share reduction plan by major shareholders, which may impact the stock's market performance and investor sentiment [1] Shareholder Reduction Plans - 深圳市信中康成投资合伙企业 plans to reduce its holdings by up to 8,890,977 shares, representing approximately 0.50% of the total share capital, within three months starting from December 8, 2025 [1] - 深圳市信中龙成投资合伙企业 intends to reduce its holdings by up to 17,781,955 shares, accounting for about 1% of the total share capital, also within three months starting from December 8, 2025 [1] - 信中康成 currently holds 223,488,310 shares, which is about 12.57% of the total share capital, while 信中龙成 holds 28,498,500 shares, approximately 1.60% of the total share capital [1]

Pharmaron Beijing Co., Ltd. 香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年11月14日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 证券代码：300759 证券简称：康龙化成 公告编号：2025-064 康龙化成（北京）新药技术股份有限公司 ...

人民财讯11月14日电，康龙化成（300759）11月14日公告，合计持股14.17%的公司股东深圳市信中康 成投资合伙企业(有限合伙)(简称"信中康成"))及其一致行动人深圳市信中龙成投资合伙企业(有限合伙) 计划合计减持公司股份不超过2667.29万股，占公司总股本的1.5%。 ...

康龙化成(300759.SZ)公告称，持股5%以上股东信中康成计划减持不超过889.10万股（占公司总股本的 0.50%），一致行动人信中龙成计划减持不超过1,778.20万股（占公司总股本的1.00%），合计减持不超 过2,667.30万股（占公司总股本的1.50%）。减持方式为集中竞价交易或大宗交易，减持原因为合伙企 业存续期限即将到期及自身资金需求，减持期间为公告披露之日起15个交易日后的3个月内。 ...

证券代码：300759 证券简称：康龙化成 公告编号：2025-064 康龙化成（北京）新药技术股份有限公司 关于持股 5%以上股东减持股份的预披露公告 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）及其一致行 动人深圳市信中龙成投资合伙企业（有限合伙）保证向本公司提供的信息内容真实、 准确和完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于近日收到 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合伙）（以下简称"信 中康成"）及其一致行动人深圳市信中龙成投资合伙企业（有限合伙）（以下简称 "信中龙成"）出具的《股份减持计划告知函》。信中康成持有公司股份 223,488,310 股（约占公司总股本的 12.57%），计划自本公告披露之日起 15 个交 易日后（2025 年 12 月 8 日）的 3 个月内以集中竞价、大宗交易等深圳证券交易 所认可的合法方式减持公司股份不超过 8,890,977 股（占公司总股本的 0.50%）； 信中龙成持有公司股份 28, ...